WE CLAIM:

Claims 1-14 (Canceled).

- 15(New). A method for treating a mammalian subject comprising the steps of:
- (a) administering to said subject having excess gastric acid, an agent selected from the group consisting of a histamine receptor blocker and a proton pump inhibitor; and
- (b) administering to said subject an immunogenic composition comprising a G17 peptide of SEQ ID NO: 1 or fragment thereof.
- 16(New). The method according to claim 15, wherein said method inhibits agent-induced side effects.
- 17(New). The method according to claim 16, wherein said side effect is hypergastrinemia.
- 18(New). The method according to claim 15, wherein the serum gastrin levels of said subject are reduced or maintained at a normal level.
- 19(New). The method according to claim 18, wherein the serum gastrin levels of said subject are reduced or maintained at less than 240 pg/mL.
- 20(New). The method according to claim 18, wherein the serum gastrin levels of said subject are reduced or maintained at less than 40 pg/mL.
- 21(New). The method according to claim 18, wherein said gastric acid production is inhibited.

- 22(New). The method according to claim 16, wherein said side effect is pernicious anemia, a gastric tumor, or a gastric cancer.
- 23(New). The method according to claim 16, wherein said side effect is a cancer selected from the group consisting of colon cancer, stomach cancer, pancreatic cancer, esophageal cancer, and liver cancer.
- 24(New). The method according to claim 16, wherein said administration occurs prior to the development of said side effect.
- 25(New). The method according to claim 15, wherein said subject has hypergastrinemia.
- 26(New). The method according to claim 15, wherein said subject has one or more of pernicious anemia, a gastric tumor, colon cancer, stomach cancer, pancreatic cancer, esophageal cancer, or liver cancer.
- 27(New). The method according to claim 15, wherein said immunogenic composition comprises said G17 peptide conjugated to an immunogenic carrier and a pharmaceutically acceptable carrier.
- 28(New). The method according to claim 15, wherein said G17 peptide fragment is linked by an amino acid spacer to an immunogenic carrier.
- 29(New). The method according to claim 28, wherein said carrier is selected from the group consisting of diphtheria toxoid, tetanus toxoid, and keylimpet hemocyanin.
- 30(New). The method according to claim 15, wherein said blocker is selected from the group consisting of ranitidine, cimetidine, fomatidine, and nizatidine.

- 31(New). The method according to claim 15, wherein said inhibitor is selected from the group consisting of omeprazole, lansoprazole, and patoprazole.
- 32(New). The method according to claim 15, wherein said subject is administered said immunogenic composition before said agent.
- 33(New). The method according to claim 15, wherein said subject is administered said agent before said immunogenic composition.
- 34(New). A method for treating a mammalian subject comprising the steps of:
- (a) administering to said subject having excess gastric acid, an agent selected from the group consisting of a histamine receptor blocker and a proton pump inhibitor; and
- (b) administering to said subject an immunogenic composition comprising anti-gastrin antibodies.
- 35(New). The method according to claim 34, wherein said antibodies bind to a G17 peptide of SEQ ID NO: 1 or fragment thereof.
- 36(New). The method according to claim 34, wherein said antibodies bind to heptadecagastrin G17.
- 37(New). The method according to claim 34, wherein said antibodies are purified, monoclonal, or humanized.
- 38(New). The method according to claim 34, wherein said method inhibits agent-induced side effects.
- 39(New). The method according to claim 38, wherein said side effect is hypergastrinemia.

- 40(New). The method according to claim 35, wherein the serum gastrin levels of said subject are reduced or maintained at a normal level.
- 41(New). The method according to claim 40, wherein the serum gastrin levels of said subject are reduced or maintained at less than 240 pg/mL.
- 42(New). The method according to claim 40, wherein the serum gastrin levels of said subject are reduced or maintained at less than 40 pg/mL.
- 43(New). The method according to claim 40, wherein said gastric acid production is inhibited.
- 44(New). The method according to claim 38, wherein said side effect is pernicous anemia, a gastric tumor, or a gastric cancer.
- 45(New). The method according to claim 38, wherein said side effect is a cancer selected from the group consisting of colon cancer, stomach cancer, pancreatic cancer, esophagael cancer, and liver cancer.
- 46(New). The method according to claim 38, wherein said administration occurs prior to the development of said side effect.
- 47(New). The method according to claim 34, wherein said subject has hypergastrinemia.
- 48(New). The method according to claim 34, wherein said subject has one or more of pernicous anemia, a gastric tumor, colon cancer, stomach cancer, pancreatic cancer, esophagael cancer, or liver cancer.
- 49(New). The method according to claim 35, wherein said immmogenic composition comprises said G17 peptide conjugated to an immunogenic carrier and a pharmaceutically acceptable carrier.

- 50(New). The method according to claim 35, wherein said G17 peptide fragment is linked by an amino acid spacer to an immunogenic carrier.
- 51(New). The method according to claim 50, wherein said carrier is selected from the group consisting of diphtheria toxoid, tetanus toxoid, and keylimpet hemocyanin.
- 52(New). The method according to claim 34, wherein said blocker is selected from the group consisting of ranitidine, cimetidine, fomatidine, and nizatidine.
- 53(New). The method according to claim 34, wherien said inhibitor is selected from the group consisting of omeprazole, lansoprazole, and patoprazole.
- 54(New). The method according to claim 34, wherein said subject is administered said immunogenic composition before said agent.
- 55(New). The method according to claim 34, wherein said subject is administered said agent before said immunogenic composition.
- 56(New). A combination for use in treating a mammalian subject comprising:
- (a) an agent selected from the group consisting of a histamine receptor blocker and a proton pump inhibitor; and
- (b) an immunogenic composition comprising a G17 peptide of SEQ ID NO: 1 or fragment thereof.